Drugs that contain Silodosin
1. Rapaflo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780485 | ALLERGAN | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(11 years ago) | |
| US5403847 | ALLERGAN | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov, 2012
(11 years ago) | |
| US6015819 | ALLERGAN | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(11 years ago) | |
| US5387603 | ALLERGAN | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2013 |
NCE-1 date: 08 October, 2012
Market Authorisation Date: 08 October, 2008
Treatment: Use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph)
Dosage: CAPSULE;ORAL
How can I launch a generic of RAPAFLO before it's drug patent expiration?
More Information on Dosage
RAPAFLO family patents
